Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Burlington, MA, US. The stock last traded at $3.81, down 0.13% on the session, giving a market capitalisation of $20.6M. On trailing twelve-month figures it carries a trailing P/E of -0.35, a net margin of 272.0%. Its beta of 0.75 implies it has historically moved less than the broad market.
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
Neuphoria Therapeutics Inc. is most often compared with the following Healthcare names: